These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 10978741

  • 1. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle.
    Adler M, Keller JE, Sheridan RE, Deshpande SS.
    Toxicon; 2001; 39(2-3):233-43. PubMed ID: 10978741
    [Abstract] [Full Text] [Related]

  • 2. Effect of 3,4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin.
    Adler M, Macdonald DA, Sellin LC, Parker GW.
    Toxicon; 1996 Feb; 34(2):237-49. PubMed ID: 8711757
    [Abstract] [Full Text] [Related]

  • 3. Antagonism of botulinum toxin A-mediated muscle paralysis by 3, 4-diaminopyridine delivered via osmotic minipumps.
    Adler M, Capacio B, Deshpande SS.
    Toxicon; 2000 Oct; 38(10):1381-8. PubMed ID: 10758273
    [Abstract] [Full Text] [Related]

  • 4. Neuromuscular paralysis and recovery in mice injected with botulinum neurotoxins A and C.
    Morbiato L, Carli L, Johnson EA, Montecucco C, Molgó J, Rossetto O.
    Eur J Neurosci; 2007 May; 25(9):2697-704. PubMed ID: 17561839
    [Abstract] [Full Text] [Related]

  • 5. 3,4-diaminopyridine reverses paralysis in botulinum neurotoxin-intoxicated diaphragms through two functionally distinct mechanisms.
    Bradford AB, Machamer JB, Russo TM, McNutt PM.
    Toxicol Appl Pharmacol; 2018 Feb 15; 341():77-86. PubMed ID: 29366638
    [Abstract] [Full Text] [Related]

  • 6. Persistence of botulinum neurotoxin action in cultured spinal cord cells.
    Keller JE, Neale EA, Oyler G, Adler M.
    FEBS Lett; 1999 Jul 30; 456(1):137-42. PubMed ID: 10452545
    [Abstract] [Full Text] [Related]

  • 7. Uptake of botulinum neurotoxin into cultured neurons.
    Keller JE, Cai F, Neale EA.
    Biochemistry; 2004 Jan 20; 43(2):526-32. PubMed ID: 14717608
    [Abstract] [Full Text] [Related]

  • 8. The role of the synaptic protein snap-25 in the potency of botulinum neurotoxin type A.
    Keller JE, Neale EA.
    J Biol Chem; 2001 Apr 20; 276(16):13476-82. PubMed ID: 11278807
    [Abstract] [Full Text] [Related]

  • 9. Botulinum neurotoxin serotype D - A potential treatment alternative for BoNT/A and B non-responding patients.
    Kutschenko A, Weisemann J, Kollewe K, Fiedler T, Alvermann S, Böselt S, Escher C, Garde N, Gingele S, Kaehler SB, Karatschai R, Krüger THC, Sikorra S, Tacik P, Wegner F, Wollmann J, Bigalke H, Wohlfarth K, Rummel A.
    Clin Neurophysiol; 2019 Jun 20; 130(6):1066-1073. PubMed ID: 30871800
    [Abstract] [Full Text] [Related]

  • 10. Effects of enzymatically inactive recombinant botulinum neurotoxin type A at the mouse neuromuscular junctions.
    Baskaran P, Lehmann TE, Topchiy E, Thirunavukkarasu N, Cai S, Singh BR, Deshpande S, Thyagarajan B.
    Toxicon; 2013 Sep 20; 72():71-80. PubMed ID: 23810945
    [Abstract] [Full Text] [Related]

  • 11. Botulinum Neurotoxins Can Enter Cultured Neurons Independent of Synaptic Vesicle Recycling.
    Pellett S, Tepp WH, Scherf JM, Johnson EA.
    PLoS One; 2015 Sep 20; 10(7):e0133737. PubMed ID: 26207366
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons.
    Foran PG, Mohammed N, Lisk GO, Nagwaney S, Lawrence GW, Johnson E, Smith L, Aoki KR, Dolly JO.
    J Biol Chem; 2003 Jan 10; 278(2):1363-71. PubMed ID: 12381720
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of neurotransmitter release by peptides that mimic the N-terminal domain of SNAP-25.
    Apland JP, Adler M, Oyler GA.
    J Protein Chem; 2003 Feb 10; 22(2):147-53. PubMed ID: 12760419
    [Abstract] [Full Text] [Related]

  • 14. Reversal of BoNT/A-mediated inhibition of muscle paralysis by 3,4-diaminopyridine and roscovitine in mouse phrenic nerve-hemidiaphragm preparations.
    Adler M, Deshpande SS, Apland JP, Murray B, Borrell A.
    Neurochem Int; 2012 Nov 10; 61(6):866-73. PubMed ID: 22841859
    [Abstract] [Full Text] [Related]

  • 15. Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system.
    Tsai YC, Maditz R, Kuo CL, Fishman PS, Shoemaker CB, Oyler GA, Weissman AM.
    Proc Natl Acad Sci U S A; 2010 Sep 21; 107(38):16554-9. PubMed ID: 20823219
    [Abstract] [Full Text] [Related]

  • 16. Correlation of cleavage of SNAP-25 with muscle function in a rat model of Botulinum neurotoxin type A induced paralysis.
    Jurasinski CV, Lieth E, Dang Do AN, Schengrund CL.
    Toxicon; 2001 Sep 21; 39(9):1309-15. PubMed ID: 11384718
    [Abstract] [Full Text] [Related]

  • 17. Transynaptic Action of Botulinum Neurotoxin Type A at Central Cholinergic Boutons.
    Caleo M, Spinelli M, Colosimo F, Matak I, Rossetto O, Lackovic Z, Restani L.
    J Neurosci; 2018 Nov 28; 38(48):10329-10337. PubMed ID: 30315128
    [Abstract] [Full Text] [Related]

  • 18. On the action of botulinum neurotoxins A and E at cholinergic terminals.
    Washbourne P, Pellizzari R, Rossetto O, Bortoletto N, Tugnoli V, De Grandis D, Eleopra R, Montecucco C.
    J Physiol Paris; 1998 Apr 28; 92(2):135-9. PubMed ID: 9782457
    [Abstract] [Full Text] [Related]

  • 19. Enhancement of the endopeptidase activity of purified botulinum neurotoxins A and E by an isolated component of the native neurotoxin associated proteins.
    Sharma SK, Singh BR.
    Biochemistry; 2004 Apr 27; 43(16):4791-8. PubMed ID: 15096048
    [Abstract] [Full Text] [Related]

  • 20. Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B.
    Wang J, Zurawski TH, Bodeker MO, Meng J, Boddul S, Aoki KR, Dolly JO.
    Biochem J; 2012 May 15; 444(1):59-67. PubMed ID: 22360156
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.